175 related articles for article (PubMed ID: 36111395)
21. Haemophagocytic syndrome and COVID-19.
Retamozo S; Brito-Zerón P; Sisó-Almirall A; Flores-Chávez A; Soto-Cárdenas MJ; Ramos-Casals M
Clin Rheumatol; 2021 Apr; 40(4):1233-1244. PubMed ID: 33389315
[TBL] [Abstract][Full Text] [Related]
22. CAR T-Cell-Associated Neurotoxicity: Current Management and Emerging Treatment Strategies.
Rivera AM; May S; Lei M; Qualls S; Bushey K; Rubin DB; Barra ME
Crit Care Nurs Q; 2020; 43(2):191-204. PubMed ID: 32084062
[TBL] [Abstract][Full Text] [Related]
23. Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience.
Dholaria B; Mehraban N; Baer B; Long N; Jayani RV; Byrne MT; Kassim AA; Engelhardt BG; Savani BN; Oluwole OO
Br J Haematol; 2022 Sep; 198(6):1073-1075. PubMed ID: 35765247
[No Abstract] [Full Text] [Related]
24. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
[TBL] [Abstract][Full Text] [Related]
25. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy.
Chen PH; Lipschitz M; Weirather JL; Jacobson C; Armand P; Wright K; Hodi FS; Roberts ZJ; Sievers SA; Rossi J; Bot A; Go W; Rodig SJ
JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32484797
[TBL] [Abstract][Full Text] [Related]
26. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT).
Nahas GR; Komanduri KV; Pereira D; Goodman M; Jimenez AM; Beitinjaneh A; Wang TP; Lekakis LJ
Leuk Lymphoma; 2020 Apr; 61(4):940-943. PubMed ID: 31793821
[TBL] [Abstract][Full Text] [Related]
27. Advances in chimeric antigen receptor T cells.
Beyar-Katz O; Gill S
Curr Opin Hematol; 2020 Nov; 27(6):368-377. PubMed ID: 32925186
[TBL] [Abstract][Full Text] [Related]
28. Familial haemophagocytic lymphohistiocytosis: two case reports.
Ferreira M; Martins J; Silvestre C; Abadesso C; Matias E; Loureiro H; Figueiredo A; Dias A; Almeida H
BMJ Case Rep; 2010 May; 2010():. PubMed ID: 22736603
[TBL] [Abstract][Full Text] [Related]
29. Consequences of hemophagocytic lymphohistiocytosis-like cytokine release syndrome toxicities and concurrent bacteremia.
Masih KE; Ligon JA; Yates B; Shalabi H; Little L; Islam Z; Ombrello AK; Inglefield J; Nussenblatt V; Manion M; Khan J; Shah NN
Pediatr Blood Cancer; 2021 Oct; 68(10):e29247. PubMed ID: 34309174
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
[TBL] [Abstract][Full Text] [Related]
31. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.
Al-Juhaishi T; Ahmed S
Curr Hematol Malig Rep; 2021 Feb; 16(1):32-39. PubMed ID: 33630232
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of hemophagocytic lymphohistiocytosis in patients in the intensive care unit].
Eichenauer DA; La Rosée P
Inn Med (Heidelb); 2023 Oct; 64(10):955-960. PubMed ID: 37702780
[TBL] [Abstract][Full Text] [Related]
33. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA; Chavez JC; Sehgal AR; William BM; Munoz J; Salles G; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Yakoub-Agha I; Oluwole OO; Fung HCH; Rosenblatt J; Rossi JM; Goyal L; Plaks V; Yang Y; Vezan R; Avanzi MP; Neelapu SS
Lancet Oncol; 2022 Jan; 23(1):91-103. PubMed ID: 34895487
[TBL] [Abstract][Full Text] [Related]
34. Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma.
Cohen JA; Ghobadi A
Expert Rev Anticancer Ther; 2022 Sep; 22(9):903-914. PubMed ID: 35786133
[TBL] [Abstract][Full Text] [Related]
35. Impact of Manufacturing Procedures on CAR T Cell Functionality.
Watanabe N; Mo F; McKenna MK
Front Immunol; 2022; 13():876339. PubMed ID: 35493513
[TBL] [Abstract][Full Text] [Related]
36. Molecular and Clinical Characteristics of Different Toxicity Rates in Anti-CD19 Chimeric Antigen Receptor T Cells: Real-World Experience.
Gavriilaki E; Mallouri D; Bousiou Z; Demosthenous C; Vardi A; Dolgyras P; Batsis I; Stroggyli E; Karvouni P; Masmanidou M; Gavriilaki M; Bouinta A; Bitsianis S; Kapravelos N; Bitzani M; Vasileiadou G; Yannaki E; Sotiropoulos D; Papagiannopoulos S; Kazis D; Kimiskidis V; Anagnostopoulos A; Sakellari I
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686529
[TBL] [Abstract][Full Text] [Related]
37. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.
Jacobs MT; Jain MD; Gao F; Nastoupil LJ; Spiegel JY; Lin Y; Dahiya S; Lunning M; Lekakis L; Reagan PM; Oluwole OO; McGuirk J; Deol A; Sehgal A; Goy A; Hill BT; Andreadis C; Munoz J; Chavez JC; Bennani NN; Rapoport AP; Vose JM; Miklos DB; Neelapu SS; Ghobadi A; Locke FL
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):753-759. PubMed ID: 35780055
[TBL] [Abstract][Full Text] [Related]
38. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma.
Papadouli I; Mueller-Berghaus J; Beuneu C; Ali S; Hofner B; Petavy F; Tzogani K; Miermont A; Norga K; Kholmanskikh O; Leest T; Schuessler-Lenz M; Salmonson T; Gisselbrecht C; Garcia JL; Pignatti F
Oncologist; 2020 Oct; 25(10):894-902. PubMed ID: 32339368
[TBL] [Abstract][Full Text] [Related]
39. Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation.
Saleh K; Arbab A; Ghez D; Bigenwald C; Cotteret S; Marzac C; Pasquier F; Pilorge S; Saada V; Vergé V; Ribrag V; Castilla-Llorente C
Immunotherapy; 2023 Apr; 15(6):401-407. PubMed ID: 36950962
[TBL] [Abstract][Full Text] [Related]
40. Haemophagocytic lymphohistiocytosis (HLH)-associated stress cardiomyopathy secondary to autoimmune conditions successfully treated with anakinra.
Khalid M; Abdalla A; McCarthy G; Stack J
BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34887291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
